Phaseline

Companies › SANGMYUNG innovation

SANGMYUNG innovation: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 3; Ophthalmology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SMO1
Dexamethasone 700μg intravitreal implant
–Phase 3Retinal Vein Occlusion With Macular EdemaJul 2027
SMZ1–Phase 3Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal VasculopathyDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07708142SMO1Phase 3Retinal Vein Occlusion With Macular EdemaOphthalmologyJul 2027
NCT07695207SMZ1Phase 3Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal VasculopathyOphthalmologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Cloudbreak Therapeutics Omikron Italia S.r.l. Viridian Therapeutics Aurion Biotech Smilebiotek Zhuhai

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.